Wingspan Investment Management Lp adds Concordia Healthcare Corp (CXRX) to its portfolio

Concordia Healthcare Corp (CXRX) : Wingspan Investment Management Lp added new position in Concordia Healthcare Corp during the most recent quarter end. The investment management firm now holds 388,776 shares of Concordia Healthcare Corp which is valued at $3,938,301 , the company said in a statement filed on Aug 15, 2016 with the SEC.Concordia Healthcare Corp makes up approximately 2.78% of Wingspan Investment Management Lp’s portfolio.

Other Hedge Funds, Including , Connor Clark Lunn Investment Management Ltd. reduced its stake in CXRX by selling 108,646 shares or 25.37% in the most recent quarter. The Hedge Fund company now holds 319,587 shares of CXRX which is valued at $3,237,416. Concordia Healthcare Corp makes up approx 0.02% of Connor Clark Lunn Investment Management Ltd.’s portfolio. Jw Asset Management sold out all of its stake in CXRX during the most recent quarter. The investment firm sold 245,400 shares of CXRX which is valued $2,485,902.Cibc Asset Management Inc reduced its stake in CXRX by selling 2,239 shares or 11.58% in the most recent quarter. The Hedge Fund company now holds 17,103 shares of CXRX which is valued at $252,953.Agf Investments boosted its stake in CXRX in the latest quarter, The investment management firm added 552 additional shares and now holds a total of 1,008 shares of Concordia Healthcare Corp which is valued at $14,908. Healthinvest Partners Ab added CXRX to its portfolio by purchasing 543,000 company shares during the most recent quarter which is valued at $9,888,030. Concordia Healthcare Corp makes up approx 4.34% of Healthinvest Partners Ab’s portfolio.

On the company’s financial health, Concordia Healthcare Corp reported $1.38 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Aug 12, 2016. Analyst had a consensus of $1.40. The company had revenue of $231.70 million for the quarter, compared to analysts expectations of $232.57 million. The company’s revenue was up 208.1% compared to the same quarter last year.

Many Wall Street Analysts have commented on Concordia Healthcare Corp. Concordia Healthcare Corp was Downgraded by CIBC to ” Sector Underperform” on Aug 15, 2016. Concordia Healthcare Corp was Downgraded by TD Securities to ” Hold” on Aug 4, 2016. Concordia Healthcare Corp was Initiated by Goldman to “Neutral” on Jun 6, 2016.

Concordia Healthcare Corp. is a Canada-based diverse healthcare company. The Company is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments which includes Legacy Pharmaceutical Division Concordia Pharmaceuticals Inc. which consists of 23 products including Nilandron for the treatment of metastatic prostate cancer; Dibenzyline for the treatment of pheochromocytoma; Lanoxin for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; Donnatal for the treatment of irritable bowel syndrome and Zonegran (zonisamide) for treatment of partial seizures in adults with epilepsy. Its Specialty Healthcare Distribution (SHD) Division Complete Medical Homecare is engaged in the distribution of medical supplies focused on diabetes and related conditions. Its Orphan Drugs Division Concordia Laboratories Inc. is engaged in the manufacture of PHOTOFRIN.

Leave a Reply

Concordia Healthcare Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Concordia Healthcare Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.